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Abstract: The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer, possibly 
due to better therapeutic approaches for control of metastatic growth in other organs. Occurrence of BMs severely affects 
quality of life and is associated with dire prognosis. In this short report we describe the clinical case of a 47 year old woman, 
with BMs from breast cancer diagnosed in May 2001. The patient was treated with whole brain irradiation and radiosurgery, 
with initial control of BMs. Due to previous radiotherapy ﬁ  elds and doses, further local treatments are not feasible anymore. 
Since September 2006, the patient has been receiving systemic therapy with Lapatinib at the dose of 1500 mg/die continu-
ously, with a good control of cerebral, liver and nodal metastasis after one year of treatment (September 2007). Her quality 
of life is acceptable, her Karnofsky Performance Status (KPS) is more than 70%, and she takes care of her family, and has 
not experienced neuro-cognitive dysfunction.
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Introduction
The incidence of brain metastases (BMs) seems to have increased over the past decade, and may be the 
paradoxical result of the effectiveness of drugs that do not cross the blood—brain barrier (BBB). As a 
result of the increased survival in patients receiving chemotherapy, BMs may become symptomatic (1). 
Occurrence of brain relapse severely affects quality of life and is associated with extremely dire prog-
nosis. Median survival after the diagnosis of symptomatic central nervous system (CNS) involvement 
is roughly 4 months, and 2-year survival is less than 2% (2, 3). When looking at radiosurgery series, a 
longer survival has been observed in selected groups of patients, with median survival ranging from 13 
to 19 months (4, 5). In a recent report (6), the median survival after diagnosis of symptomatic cerebral 
metastases in 72 patients with metastatic breast cancer treated in our Insitution was nine months.
Breast carcinoma is the second most common cause of BMs, which occur in approximately 10%–15% 
of patients, although autopsy data suggest a higher prevalence up to 30% of patients (2, 7). Furthermore, 
breast cancer (BC) is the most common solid tumour to exhibit leptomeningeal colonization (8, 9).
A strong correlation with paclitaxel-based chemotherapy and cerebral relapse has previously been 
observed (1). Patients with endocrine unresponsive tumours seem at increased risk of developing cere-
bral metastases (1, 2). Recently, it has also been reported a higher risk of developing brain recurrence 
in young patients with Her-2/neu over-expression (10, 11), and in patients treated with trastuzumab-
based therapy, with observed incidence rate variable from 25% to 34% (12, 13). The mechanism pos-
tulated is that Trastuzumab therapy may selectively destroy non BMs, prolong overall survival, 
therefore allowing a later development of cerebral relapse.
Patients with Her-2/neu over-expressing tumours had apparently a longer survival after the 
occurrence of BMs, compared with patients whose cancer did not express Her-2/neu. This survival 
advantage may be possibly explained by a better control of extra-cranial disease in this subgroup of 
patients, due to trastuzumab-based treatments (13). Data are not consistent in all reports (14), but in 
several studies the majority of patients with BMs and visceral disease died of progressive extra-cranial 
disease (15, 16).
Recursive partitioning analysis (RPA) of data from three Radiation Therapy Oncology Group (RTOG) 
trials (1200 patients) has allowed three prognostic groups of patients with BMs to be identiﬁ  ed. RPA 
class was initially developed to categorize patients treated with fractionated external beam brain RT 104
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and tested in the radiosurgical treatment of BMs 
(17). Data have been validated in subsequent series 
(18), and RPA classes are extremely useful in esti-
mating median survival of patients with brain 
recurrence according to different variables. More 
recently, Lorenzoni et al. proposed a simpliﬁ  ed 
stratiﬁ  cation system that uses the evaluation of 
three main prognostic factors for radiosurgery in 
BMs; this system was called of basic score for BMs 
(BS-BM), and may be calculated by adding the 
scores (0 or 1) of three main prognostic factors: 
Karnofsky Performance Status (KPS), control of 
the primary tumor, and existence of extracranial 
metastases, ranging from 0 (worst condition) to 3 
(best condition) (19).
Case Report
In this short paper, we describe a 47 years old 
woman with advanced breast cancer and brain 
relapse diagnosed in May 2001.
The patient underwent right mastectomy plus 
ipsi-lateral node dissection for breast tumour on 
the 19th of May 1995. Histopathological diagnosis 
was of high grade ductal inﬁ  ltrating carcinoma, 
staging pT3 pN1 (4 out of 13 nodes involved) M0. 
Biological characteristics were as follows: negative 
oestrogen and progesteron receptors, ki 67 of 20%, 
and HER2/neu over-expression determined by 
immuno-histochemistry. She received adjuvant 
chemotherapy with doxorubicin (75 mg/m
2) × 4 
cycles, followed by standard CMF day 1° and 8° 
q 28 given endovenously for 4 cycles and comple-
mentary radiotherapy.
In September 1996, for a subcutaneous and 
axillary recurrence, she underwent pre-operative 
high-dose chemotherapy with Ifosfamide plus 
Cisplatin and Etoposide, and in March 1997 she 
performed residual lymph-node dissection with 
diagnosis of nodal metastasis in 3 out of 4 nodes. 
She then received further ‘adjuvant’ systemic treat-
ment with Cisplatin (at the dose of 90 mg/m
2 day 
1/q21) and 5-ﬂ  uorouracil given as continuous infu-
sion (dose of 200 mg/m
2) and radiotherapy in the 
axilla. In June 1998, she developed liver and nodal 
metastases. She was treated with Paclitaxel at the 
dose of 90 mg/m
2 as a 96 h infusion in association 
with Vinorelbine at the dose of 15 mg/m
2 day one 
and five every 21 days, resulting in complete 
clinical response. In April 1999, for liver progres-
sion (apparently isolated metastasis) she underwent 
intra-arterial hepatic chemotherapy with Docetaxel, 
with a complete clinical response, but few months 
later, in December 1999 she presented with liver 
and nodal recurrence.
She ﬁ  rst underwent VI segment liver resection, 
and considering response to previous treatments, 
she started again systemic therapy with Paclitaxel 
(96 h infusion) and Vinorelbine for further 
4 cycles, with initial response. From the second 
cycle, she added weekly Trastuzumab, with 
achievement of a clinical complete response. She 
continued Trastuzumab until May 2001, when she 
developed symptomatic BMs. Brain MRI showed 
the presence of 3 lesions, two located in the left 
cerebellum, the major with diameter 2.3 cm × 
1.7 cm, the third in the right parietal lobe, with 
diameter of 2 cm.
Imaging showed persistence of response in 
extra-cranial sites of disease. In June 2001 she 
received whole brain irradiation with linear accel-
erator (20 Gy in 5 fractions), with a clinical par-
tial response, and subsequently she underwent 
gamma-knife (15 Gy) of the two residual lesions 
(one in the left cerebellum, and one in the right 
parietal lobe) with achievement of a complete 
response.
At the end of radiotherapy in August 2001, 
she started again maintainance treatment with 
Trastuzumab until 25th of February 2002 (per-
sistence of visceral and cerebral complete 
response). She then discontinued treatment and 
she was free of progression until August 2004, 
when brain CT scan showed a cerebellar lesion, 
apparently isolated. Considering the peculiar 
evolution, and the patient’s preference, she was 
treated with stereotactic radiosugery in 
September 2004 (DS 20 Gy e DM 40 Gy) with 
a partial response and subsequently with surgi-
cal resection of the remaining lesion to ride-
termine the biological characteristics of the 
tumour. The histopathological diagnosis was 
consistent with that of the primary tumour: 
BMs attributable to breast origin, with oestro-
gen and progesterone receptor negative and 
Her-2/neu over-expression in more than 95% 
of tumour cells, determined by immuno-
histochemistry.
In January 2006 brain imaging showed cere-
bral progression (single parietal metastases), and 
the patient was treated on the 8th of February 
2006 with gamma-knife (15 Gy). As expected, 
in the following months, cerebral disease pro-
gressed again (with persistence of complete 105
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response in the visceral sites of disease). Brain 
imaging showed the appearance of a cerebellar 
mass in the site of previous radiosurgery, and 
surgical resection.
A savage systemic treatment with Carboplatin 
(AUC 4, on day 1) plus Gemcitabine at the dose 
of 1000 mg/m
2 day 1 and 8, every 21 days, and 
trastuzumab (at a weekly schedule for three cycles, 
and with tri-weekly administration for further 3 
cycles) was then started but the therapy was 
ineffective and cerebral disease worsened again 
(Fig. 1 → Axial post-contrast T1-weighted MR 
image obtained before treatment with Lapatinib 
-September 2006- shows BMs as enhancing mass, 
involving cranial lobe of cerebellum, temporal and 
occipital lobe, with longest diameter of 48.6 mm). 
From the 15th of September 2006 she started 
treatment with Lapatinib, an oral tyrosine kinase 
Figure 1106
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inhibitor with potent anti-Erb1 and Erb2 activity, 
at the dose of 750 mg bid daily (total 1500 mg) 
in the context of a Multicentric Phase II trial 
including patients with HER2/neu over-express-
ing advanced breast cancer pre-treated with 
Trastuzumab, and with progressive BMs. The 
treatment was well tolerated, with no G3 related 
toxicity. The patient complained of mild fatigue, 
G2, visual disturbances, and cutaneous rash 
(G2). All the symptoms improved modifying 
the schedule of administration (1500 mg once 
per day).
On the 5th of June 2007 a PET total body 
including the study of the brain was negative with 
no evidence of metabolic activity in the sites of 
disease.
She recently performed a neck, thorax and abdo-
men CT scan on the 24th of September 2007 which 
conﬁ  rmed the persistence of complete visceral 
response (liver or nodal). A brain MRI (18th of 
September 2007) showed dimensional stability of 
cerebral lesions, with no occurrence of new sites 
of disease (Fig. 2 → Axial post-contrast T1-
weighted MR image obtained after treatment with 
Lapatinib -September 2007- shows longest 
diameter of 47.8 mm for the BMs, which is stable 
disease, according to response evaluation criteria 
in solid tumors (RECIST).
The patient has an acceptable quality of life, her 
KPS is more than 70%, she takes care of her family, 
and has not experienced neuro-cognitive dysfunc-
tion. She is not receiving other supportive treat-
ments (i.e. cortisonic therapy) with the exception 
of ranitidine 300 mg/die.
Discussion
In our experience, we have rarely seen such a long 
survival in a patient with brain relapse from breast 
cancer and in presence of visceral involvement. 
This observation is of peculiar value if we consider 
that the patient belongs to RPA class II, with a 
described median survival ranging from 3.8 months 
to 4.2 months and a 1-year survival ranging from 
of 12% and 16% (18, 17).
In a recent report (6), the median survival after 
diagnosis of cerebral metastases in 72 patients with 
metastatic breast cancer treated in our Insitution was 
nine months. In this paper we observed a signiﬁ  -
cantly higher rate of negative oestrogen receptor, 
negative progesterone receptors, HER2/neu over-
expression and immunostaining for Ki67  20% in 
the univariate analysis, comparing the study group 
with the control cohort. At multivariate analysis, 
HER2/neu over-expression and Ki67  20% were 
independent predictive factors of brain relapse and 
endocrine unresponsive tumours (both ER and PgR 
 10%) showed an increased risk of central nervous 
system recurrence of borderline signiﬁ  cance.
In tumours over-expressing Her2/neu, BMs 
seem to mantain the biological phenotype. The 
clinically important obstacle of delivering trastu-
zumab to an intracerebral metastasis was addressed 
by Grossi et al. (20). These investigators modeled 
HER2-overexpressing BMs in athymic rats. They 
implanted a human breast cancer cell line that 
overexpressed HER2 into the brain by intracerebral 
injection. The rats were treated with Trastuzumab 
or a control, isotype-matched antibody using a 
microinfusion technique that utilizes bulk ﬂ  ow 
current (convection) to deliver large proteins into 
the brain. Trastuzumab or the control antibody 
was administered regionally via an intracerebral 
cannula directly into the tumor for 7 days. Animals 
treated with intracerebral microinfusion of Trastu-
zumab had significantly improved survival 
compared with controls. However, systemic 
administration of Trastuzumab via i.p. microinfu-
sion failed to deliver the drug to the brain and did 
not signiﬁ  cantly affect survival. These results 
demonstrate that Her-2/neu over-expressing breast 
cancer, which is growing in the brain, can be 
targeted with HER2-directed therapy if the drug 
penetrates the CNS (20).
Lapatinib is an oral receptor tyrosine kinase 
inhibitor, inhibiting both the ErbB-1 and ErbB-2 
receptors. Lapatinib has been shown to have activ-
ity in ErbB-2-overexpressing breast cancer in 
several phase II and III clinical trials. Speciﬁ  cally, 
Lapatinib is effective in patients with metastatic 
breast cancer, with inﬂ  ammatory breast cancer, and 
possibly, with BMs (21).
Clinical trials have been carried out with 
Lapatinib for the treatment of BMs. Results from 
a phase II trial with Lapatinib for Her-2/neu over-
expressing breast cancer patients with new or 
progressing BMs were presented at the 2006 
American Society of Clinical Oncology (ASCO) 
Annual Meeting. (22). In that study, patients 
received oral Lapatinib at a dose of 750 mg twice 
daily. The primary end point was objective 
response in the central nervous system. Thirty-nine 
patients who had developed CNS disease during 
treatment with Trastuzumab were enrolled. By the 107
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Response Evaluation Criteria in Solid Tumors 
(RECIST), two patients (5%) had a partial 
response (PR) as the best CNS response and 4 of 
16 patients (25%) with measurable disease had a 
PR as the best non-CNS response. Eight patients 
had stable disease (SD) in the CNS at 16 weeks. 
Lapatinib was well tolerated in this patient popu-
lation and there was some evidence of CNS 
clinical activity.
Conclusions
The design of therapeutic and preventive approaches 
to brain relapse would further beneﬁ  t from an 
increased understanding of the blood-brain and 
blood-tumour barriers as well as other host-tumour 
interactions in the CNS. In high risk patients, the 
use of adjuvant therapies potentially active against 
cerebral metastases (Lapatinib) should be prospec-
tively investigated.
Figure 2108
Sanna et al
Clinical Medicine: Oncology 2008:2 
References
[1]  Crivellari, D., Pagani, O., Veronesi, A. et al. 2001. International Breast 
Cancer Study Group. High incidence of central nervous system 
involvement in patients with metastatic or locally advanced breast 
cancer. Ann. Oncol., 12:353–6.
[2]  DiStefano, A., Yong Yap, Y., Hortobagy, G.N. et al. 1979. The natu-
ral history of breast cancer patients with brain metastases. Cancer, 
44:1913–8.
[3] Zimm,  S.,  Wampler, G.L., Stablein, D. et al. 1981. Intracerebral 
metastases in solid tumour patients: natural history and results of 
treatment. Cancer, 48:384–94.
[4]  Goyal, S., Prasad, D., Harrell, F. Jr., et al. 2005, Aug. Gamma knife 
surgery for the treatment of intracranial metastases from breast 
cancer. J. Neurosurg., 103(2):218–23.
[5]  Akyurek, S., Chang, E.L., Mahajan, A. et al. 2007, Jun. Stereotactic 
radiosurgical treatment of cerebral metastases arising from breast 
cancer. Am. J. Clin. Oncol., 30(3):310–4.
[6] Sanna,  G.,  Franceschelli,  L., Rotmensz, N. et al. 2007, Jul-Aug. Brain 
metastases in patients with advanced breast cancer (ABC). Antican-
cer Res., 27(4C):2865–9.
[7]  Corej, J., Langer, Minesh, P. Metha, 2005. September 1. Current 
management of brain metastases, with a focus on systemic options. 
Journal of Clinical Oncology, 23(25):6207–19.
[8]  Sawaya, R., Bindal, R., Lang, F. et al. 2001. Metastatic Tumours. 
brain tumours: An Encyclopedic Approach. edited by Kaye AH, Laws 
ER., Jr., New York. Churchill Livingstone, pp. 999–1026.
[9]  Weil, R.J., Palmieri, D.C., Bronder, J.L. et al. 2005. October. Breast 
Cancer Metastasis to Central Nervous System, Review. American 
Journal of Pathology, 167(4):913–20.
[10]  Altaha, R et., Cromwell, E., Hobbs Gerry. et al. 2005, Feb 1. Increased 
risk of brain Metastases in Patients with HER-2/neu—positive Breast 
Carcinoma. Cancer, 103(3):442–3.
[11]  Miller, K.D., Weathers, L., Haney, G. et al. 2003, Jul. Occult central 
nervous system involvement in patients with metastatic breast cancer: 
prevalence, predictive factors and impact on overall survival. Ann. 
Oncol., 14(7):1072–7.
[12]  Clayton, A., Danson, S., Jolly, S., Ryder, W. et al. 2004. Incidence 
of cerebral metastases in patients treated with trastuzumab for meta-
static breast cancer. Br. J. Cancer, 91:639–43.
[13]  Kirsch, D.G., Carlos, J., Ledezma, Christina, S. et al. 2005, Mar. 
Survival after brain metastases from breast Cancer in the Trastuzumab 
Era, 2005. J. Clin. Oncol., 23(9):2114–6.
[14]  Lai, R., Dang, C.T., Malkin, M.G. et al. 2004, August 15. The risk 
of Central Nervous System Metastases after Trastuzumab Therapy 
in Patients with Breast Cancer. Cancer, 101(4):810–6.
[15]  Viani, G.A., Castilho, M.S., Salvajoli, J.V. et al. 2007, Mar. Whole 
brain radiotherapy for brain metastases from breast cancer: estimation 
of survival using two stratiﬁ  cation systems. BMC Cancer, 26;7:53.
[16]  Muacevic, A., Kreth, F.W., Tonn, J.C. et al. 2004, Apr. Stereotactic 
radiosurgery for multiple brain metastases from breast carcinoma. 
Cancer, 100(8):1705–11.
[17]  Gaspar, L., Scott, C., Rotman, M. et al. 1997, Mar. Recursive parti-
tioning analysis (RPA) of prognostic factors in three Radiation 
Therapy Oncology Group (RTOG) brain metastases trials. Int. J. 
Radiat. Oncol. Biol. Phys., 37(4):745–51.
[18]  Gaspar, L.E., Scott, C., Murray, K. et al. 2000, Jul 1. Validation of 
the RTOG recursive partitioning analysis (RPA) classiﬁ  cation for 
brain metastases. Int. J. Radiat. Oncol. Biol. Phys., 47(4):1001–6.
[19]  Lorenzoni, J., Devriendt, D., Massager, N. et al. 2004, Sep 1. Radio-
surgery for treatment of brain metastases: estimation of patient eli-
gibility using three stratiﬁ  cation systems. Int. J. Radiat. Oncol. Biol. 
Phys., 60(1):218–24.
[20] Grossi, P.M., Ochiai, H., Archer, G.E. et al. 2003. Efﬁ  cacy of 
intracerebral microinfusion of trastuzumab in an athymic rat model 
of intracerebral metastatic breast cancer. Clin. Cancer Res., 
9:5514–20.
[21]  Moy, B. and Goss, P.E. 2006, Nov-Dec. Lapatinib: current status and 
future directions in breast cancer. Oncologist, 11(10):1047–57.
[22] Lin,  N.U., Carey, L.A., Liu, M.C. et al. 2006. Phase II trial of lapatinib 
for brain metastases in patients with HER2 breast cancer. J. Clin. 
Oncol., 24(suppl 18):3S.